Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
Viking liver disease drug reduces fibrosis in final ph. 2 data
The drug reduced liver fat content by an average of 37% to 55%, with all treatment arms showing significant improvements compared to placebo.
Darren Incorvaia
Nov 20, 2024 3:20pm
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
Mar 13, 2024 9:54am
Boehringer links GLP-1 agonist to scarring improvements in MASH
Feb 26, 2024 6:17am
